Get the Stockscreener App
0.5802
1.05%
-0.0009
Veru Inc stock is traded at $0.5802, with a volume of 2.63M.
It is down -1.05% in the last 24 hours and down -22.75% over the past month.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
See More
Previous Close:
$0.5811
Open:
$0.595
24h Volume:
2.63M
Relative Volume:
0.93
Market Cap:
$80.51M
Revenue:
$15.93M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.7736
EPS:
-0.75
Net Cash Flow:
$-59.50M
1W Performance:
+3.47%
1M Performance:
-22.75%
6M Performance:
-25.23%
1Y Performance:
+30.68%
1-Day Range:
$0.5428
$0.5994
1-Week Range:
$0.534
$0.62
52-Week Range:
$0.3612
$1.92
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
(312) 595-9123
Address
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
0.575 | 80.51M | 15.93M | -64.59M | -59.50M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.13 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
713.01 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.97 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.79 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.16 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-24 | Initiated | B. Riley Securities | Buy |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Jun-07-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jul-03-18 | Initiated | Maxim Group | Buy |
View All
Veru Inc Stock (VERU) Latest News
Veru Inc [VERU] Records 50-Day SMA of $0.7280 - Knox Daily
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025 - GlobeNewswire
Veru (VERU) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Veru Earnings Call Alert: Q1 2025 Results Coming Next WeekWhat's at Stake for this Biotech Pioneer - StockTitan
Veru Inc (VERU) Shares Down Despite Recent Market Volatility - The News Heater
Veru Inc (VERU Stock: A Sea of Opportunity - The InvestChronicle
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Veru Inc (VERU) is looking forward to a strong quarter - SETE News
What will the future hold for Veru Inc (NASDAQ:VERU) stock? - US Post News
Oppenheimer maintains Veru stock Outperform rating, $5 target - MSN
Veru (VERU) to Release Quarterly Earnings on Thursday - Defense World
Veru shares plunge despite positive data in obesity trial - pharmaphorum
Oppenheimer maintains Veru stock Outperform rating, $5 target By Investing.com - Investing.com Canada
Veru Hopes To Improve The QUALITY Of Drug-Induced Weight Loss - News & Insights
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher - Benzinga
Veru’s Drug Spares Lean Mass in Overweight, Obese Adults on Wegovy—Is It Enough? - BioSpace
Muscle-building drug improves body composition in obesity trial, Veru says - BioPharma Dive
Dow Edges Higher; AT&T Posts Upbeat Earnings - Benzinga
Veru's experimental drug helps older obese patients on Wegovy preserve muscle - Reuters
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough - Benzinga
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December - Benzinga
Veru down 46% despite data for drug preserving lean body mass in Wegovy users - Seeking Alpha
Veru Reports Positive Data From Phase 2b QUALITY Study - Nasdaq
Veru’s enobosarm meets primary endpoint in Phase 2b weight reduction trial - TipRanks
Veru says its drug preserved lean mass in patients taking Wegovy - STAT
Veru Announces Positive Topline Data from Phase 2b QUALITY - GlobeNewswire
Veru's Enobosarm + Wegovy Trial Shows 71% Better Muscle Preservation in Weight Loss Study - StockTitan
Oppenheimer maintains Veru stock Outperform rating as trial nears - MSN
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now? - MSN
Novo weight-loss data roll out; Veru ‘leans’ in - BioWorld Online
Oppenheimer maintains Veru stock Outperform rating as trial nears By Investing.com - Investing.com Canada
Investors Purchase High Volume of Veru Call Options (NASDAQ:VERU) - Defense World
Veru Target of Unusually High Options Trading (NASDAQ:VERU) - MarketBeat
Investors Buy Large Volume of Veru Call Options (NASDAQ:VERU) - MarketBeat
Jane Street Group LLC Has $74,000 Stock Holdings in Veru Inc. (NASDAQ:VERU) - Defense World
3 US Penny Stocks With Market Caps Under $200M To Consider - Simply Wall St
Will QUALITY Add More Weight To Veru Stock? - RTTNews
What is B. Riley's Forecast for Veru Q1 Earnings? - MarketBeat
What is B. Riley’s Forecast for Veru Q1 Earnings? - Defense World
Veru Inc. (NASDAQ:VERU) Shares Purchased by Geode Capital Management LLC - Defense World
Barclays PLC Has $142,000 Stock Holdings in Veru Inc. (NASDAQ:VERU) - Defense World
H.C. Wainwright maintains target on Veru stock post-sale By Investing.com - Investing.com Nigeria
Veru Inc. Sells FC2 Business to Focus on Biopharma - TipRanks
Veru Inc Stock (VERU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Veru Inc Stock (VERU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BARNETTE K GARY | Chief Scientific Officer |
May 24 '24 |
Buy |
1.34 |
5,000 |
6,696 |
5,000 |
| STEINER MITCHELL SHUSTER | President and CEO |
May 24 '24 |
Sale |
1.23 |
63,379 |
78,102 |
6,942,709 |
| STEINER MITCHELL SHUSTER | President and CEO |
May 22 '24 |
Sale |
1.39 |
6,504 |
9,018 |
7,006,388 |
| STEINER MITCHELL SHUSTER | President and CEO |
May 23 '24 |
Sale |
1.35 |
300 |
405 |
7,006,088 |
| FISCH HARRY | Chief Corporate Officer |
May 15 '24 |
Buy |
1.49 |
6,711 |
9,999 |
770,736 |
| STEINER MITCHELL SHUSTER | President and CEO |
May 15 '24 |
Sale |
1.50 |
84,021 |
125,813 |
7,100,746 |
| STEINER MITCHELL SHUSTER | President and CEO |
May 16 '24 |
Sale |
1.41 |
59,788 |
84,128 |
7,040,958 |
| STEINER MITCHELL SHUSTER | President and CEO |
May 17 '24 |
Sale |
1.32 |
28,066 |
36,988 |
7,012,892 |
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):